Maurizio D Amico M.D.

Similar documents
Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY)

Is TAVR the treatment of choice for high risk diabetic patients with aortic stenosis? Insights from the FRANCE2 Registry

The Role of TAVI in high-risk and normal-risk Patients

Le TAVI pour tout le monde?

TAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Aortic valve implantation using the femoral and apical access: a single center experience.

TAVR: Review of the Robust Data from Randomized Trials

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

Is Stroke Frequency Declining?

TAVR IN INTERMEDIATE-RISK PATIENTS

Transcatheter Aortic Valve Replacement

TAVI in Korea, How to Avoid Conduction

Strokes After TAVR Reasons for Declining Frequency

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre

TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con

RANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING

TAVI in Rabin Medical Center -

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

Effect of Availability of Transcatheter Aortic-Valve Replacement on Clinical Practice

TAVR for low-risk patients in 2017: not so fast.

Aortic Stenosis: Background

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France

Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France

TAVI After PARTNER-2 : The Hamilton Approach

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy

Strokes After TAVR. Ioannis Iakovou, MD, PhD. Interventional Cardiology Onassis Cardiac Surgery Center

TAVI: Nouveaux Horizons

Indication, Timing, Assessment and Update on TAVI

Post-TAVI Cerebral Embolisms and Potential Protection Means

TAVI: 10 Years After the First Case Low-Risk and High-Risk Patients What are the Limits? Dr Bernard Prendergast DM FRCP FESC John Radcliffe Hospital

Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.

Valvular Intervention

PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.

Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School

TAVR Transaortic Approach: New Trends in Aortic Valve Surgery

Transcatheter Aortic-Valve Implantation for Aortic Stenosis

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR

A new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center

Transcatheter Aortic-Valve Implantation for Aortic Stenosis

Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Interventional solutions for atrial fibrillation in patients with heart failure

TAVI limitations for low risk patients

One Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry

TAVR SPRING 2017 The evolution of TAVR

TAVR: Intermediate Risk Patients

Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS

3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong

1-YEAR OUTCOMES FROM JOHN WEBB, MD

Transcatheter Therapies For Aortic Valve Disease. March 2017 Brian Whisenant MD

Predictors, incidence and outcomes of patients undergoing transcatheter aortic valve implantation complicated by stroke

Facteurs prédic.fs de mauvais pronos.c à court terme après TAVI

Minimally invasive aortic valve surgery: new solutions to old problems.

Transcatheter Valve Replacement: Current State in 2017

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

Disclosures 4/16/2018. What s New in Valvularand Structural Heart Disease. None relevant to the presentation

Transcatheter aortic valve replacement is considered investigational for all other indications.

Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients

Predictors of length of stay and duration of tracheal intubation after transcatheter aortic valve implantation

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system

In Process, Unpublished STS/ACC TVT Registry Manuscripts

Coronary interventions

TAVI EN INSUFICIENCIA AORTICA

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

Transcatheter Aortic-Valve Implantation for Aortic Stenosis

Mitral Valve Disease, When to Intervene

Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update

Results of Transfemoral Transcatheter Aortic Valve Implantation

e Corrado Tamburino, MD, PhD

Aortic Stenosis in the Elderly: Difficulties for the Clinician. Are Symptoms Due to Aortic Stenosis?

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes

Transcatheter Aortic-Valve Implantation for Aortic Stenosis

Vinod H. Thourani, MD, FACC, FACS

Severe Aortic Valve Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative

Case Presentations TAVR: The Good Bad and The Ugly

Results of Transapical Valves. A.P. Kappetein Dept Cardio-thoracic surgery

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

Long-Term Outcomes of Conventional Aortic Valve Replacement in High-Risk Patients: Where Do We Stand?

Prof. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation

SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes

Low Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor

Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco

Transcatheter aortic valve implantation for aortic stenosis

Trend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience

Paravalvular Regurgitation is a Risk Factor Following TAVI

TAVR y Enfermedad Coronaria. Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine

LOW RISK TAVR. WHAT THE FUTURE HOLDS

Transcatheter aortic valve implantation and pre-procedural risk assesment

The Impact of TAVI Nurse Coordinator on patient management of Transcatheter Aortic Valve Implantation (TAVI) program in QEH

Aortic stenosis (AS) remains the most common

stenosis (AS) at our center between June 2007 and December 2010, with last follow-up contact in 2016.

Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea

Corrado Tamburino, MD, PhD

Transcription:

TAVI BEST CANDIDATE AND OPTIMIZED LONG TERM FOLLOW-UP Maurizio D Amico M.D. Dipartimento Cardiovascolare e Toracico Città della Salute e della Scienza, Turin Italy

Regional Guidelines for TAVI implantation Indicazioni all impianto di protesi aortiche trans-catetere (Percutanee e Transapicali) D.G.R. n 16 11109 del 30/03/2009 1. Stenosi aortica valvolare severa 2. Elevato/proibitivo rischio chirurgico: Euroscore additivo > 10 3. Parere multidisciplinare di non operabilità 4. Parere combinato cardiologo interventista, cardiochirurgo, anestesista rianimatore 5. Presenza di unità operativa di cardiochirurgia 6. Parere del paziente (l esplicita richiesta del pz non può essere considerata un indicazione al trattamento) 7. Consenso informato scritto

RISK SCORE EUROSCORE Logistic EUROSCORE Standard EUROSCORE II STS score PROCEDURAL SUCCESS LEE score ADL score 15 feets walking test Prension test FRAILTY

J Cardiovasc Med 2013, 14:894 898 In TAVI patients, ACEF score, STS score and Logistic Euroscore provided only a moderate correlation and a low accuracy both for 30-day and medium-term outcomes. Dedicated scores are needed to properly tailor time and kind of approach.

PREDICTORS BASELINE PROCEDURAL PERI-PROCEDURAL COMPLICATION

30-day mortality Ludman et al. Circulation. 2015;131:1181-1190. DOI: 10.1161 moderately impaired left ventricular function (left ventricular ejection fraction, 30% 49%) peripheral vascular disease COPD creatinine >200 μmol/l Logistic EuroSCORE, 40 At multivariate analysis only Logistic EuroSCORE, 40 was independent predictor of 30-days mortality. The 30-day mortality: 9.7% in in 2007 and 2008 and 5.8% in 2012(P=0.089).

Predictors of mortality at 3 and 5 years 5 years Renal dysfunction LOW EF atrial fibrillation, logistic EuroSCORE > 18.5 chronic obstructive pulmonary disease Age CAD Duncan et al, J Am Coll Cardiol Intv 2015;8:645 53

Martine Gilard et al, for the FRANCE 2 investigators, NEJM - an increased logistic EuroSCORE - NYHA functional class III or IV versus class I or II - transapical approach versus transfemoral approach - periprosthetic regurgitation grade of 2 or higher versus a grade of less than 2

TAVI patients from June 2007 to December 2012 at 6 institutions 464 female and 372 male Am J Cardiol 2014;114:1269e1274 Independent predictors of adverse events at midterm follow-up in the overall population. Independent predictors of adverse events at midterm follow-up according to gender (red, female patients; blue, male patients; green, all patients)..

BASELINE PREDICTORS

Ann Thorac Surg 2015;99:809 16 30-days mortality Six studies 6,645 patients were included 50% women EuroSCORE 26.2 vs 22.4 women vs men Mid-term mortality Significantly higher risk of major bleeding, vascular complications and a lower rate of postprocedural moderate to severe aortic regurgitation in women compared with men

Conrotto et al Am J Cardiol 2014;113:529e534 Procedural characteristics and in-hospital outcomes Diabetes does not significantly affect rates of procedural complications in TAVI patients, but a trend of higher short-term mortality in diabetic patients was recorded

Am J Cardiol 2014;113:529e534 Mid-term follow-up After multivariable adjustment, insulin-treated DM was independently correlated with death and myocardial infarction

2472 patients mean follow-up 452 d (357 585) Int J Cardiol. 2013 Oct 3;168(3):2528-32.

International Journal of Cardiology 181 (2015) 77 80 Impact of residual Syntax less than 10 (9 12) on all cause death at 30 days No impact of residual Syntax less than 10 (9 12) on acute myocardial infarction, stroke and AKI at 30 days Patients with a Syntax score 10 seem to undergo TAVI procedure without additional risk

International Journal of Cardiology 167 (2013) 1514 1518 72 patients with a preserved renal function 219 with moderate CKD 73 with severe CKD Period: January 2007 to December 2011 Median follow-up of 540±250 days. Patients with severe renal disease showed a trend toward a high risk of complications, bleeding and stroke, and of death After TAVI implantation especially patients with severe kidney impairment showed an improvement in renal function

PROCEDURAL and POST-PROCEDURAL PREDICTORS

Am J Cardiol 2015;115:1720e1725 Mortalità a lungo termine Risks of moderate or severe AR and pacemaker implantation were lower with the balloon-expandable devices

J Interven Cardiol 2014;27:500 50 10468 pts Median age: 82 years 50% male Studies from 2005-2012 Mean Logistic EuroSCORE more than 20% in all the studies, except for one (18.5%), Logistic EUROSCORE higher in TA patients if compared to TF patients in the 4 studies that reported it Mean STS score > 5%

J Interven Cardiol 2014;27:500 50 Pooled adjusted odds ratio for peri-procedural bleedings

J Interven Cardiol 2014;27:500 50 Pooled adjusted odds ratio for peri-procedural stroke

J Interven Cardiol 2014;27:500 50 Pooled adjusted odds ratio for 30-days mortality

J Interven Cardiol 2014;27:500 50 Pooled adjusted odds ratio for mid-term mortality (1 y)

J Interven Cardiol 2014;27:293 299 At 30 days and mid-term follow-up all cause and cardiovascular deaths were higher in patients with bleeding compared to the no bleeding group

J Interven Cardiol 2014;27:293 299 Cox multivariate analysis for 30 days all cause death. Cox multivariate analysis for mid term all cause death. Life-threatening and major bleedings, procedural GFR<30 ml/min were independent predictors of death. Procedural GFR<30 ml/min and male gender were independent predictors of death

STROKE and TAVI - METANALISYS Independent predictors of stroke at 30 days (variables with * have been reported in at least two studies) Incidence of stroke, of TIA and of stroke or TIA at 30 days. Work in progress, Turin 2015

STROKE and TAVI - META-ANALYSIS Independent predictors of stroke at follow up Incidence of stroke, of TIA and of stroke or TIA after a follow up of 14 (11-17) months. Work in progress, Turin 2015

Predictors of 30-days mortality

Predictors of 1 year mortality

Am J Cardiol 2014;114:1867e1874 1,064 patients from 6 institution Period: January 2007- December 2012

Risk score

Main outcome of trials 30 days mortality 12 10 8 6 4 2 5 3,4 3,3 9,8 0 Partner Trial (2010) Inoperable Partner Trial 2011 (high risk) U.S. CoreValve 2014 (High risk) U.S. CoreValve 2014 (Extreme risk)

20 Main outcomes of principal registries 30 days mortality 15 10 5 0 5,4 10,8 8,5 7,6 5,1 7 6,3 3,7% 30 days mortality Italian registry 2011 (Tamburino) SOURCE registry 2011 (Wendler) FRANCE 2 Registry 2012 (Gilard) TF TVT Registry 2013 (Mack) GARY Hamm (2013) TV TVT Registry Holmes (2015) UK Registry Ludman (2015) TURIN last 100 pts

Main outcomes of principal registries 1 year mortality 40 35 30 25 20 15 10 5 0 23,1 21,7 18,3 19,4 12,2 1-y mortality Italian registry 2011 (Tamburino) FRANCE 2 Registry 2012 (Gilard) TF TVT Registry Holmes (2015) UK Registry Ludman (2015) SOURCE XT Registry (2015) 16% TURIN last 100 pts

ANTI-PLATELETS THERAPY

2014 AHA/ACC Valvular Heart Disease Guideline

JACC Vol. 62, No. 25, 2013:2349 59

Canadian Journal of Cardiology Volume 31 2015

CONCLUSIONS According to Guidelines only high risk patients should be treated Surgical risk scores fail to accurately predict mortality after transcatheter aortic valve implantation: dedicated scores are needed Heart Team still remain foundamental in patient s selection Promising performance of second generation devices

Thanks for attention